neuraxis inc said it is planning an initial public offering of 1875 million shares and expects it to price at between 7 and 9 per share the company said it is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children neuraxis applied to list its shares on the nasdaq capital market under the symbol nrxs alexander capital lp is listed as the offerings sole bookrunning manager